Study details
Enrolling now
REGENERATE-PD Trial
AskBio Inc
NCT IDNCT06285643ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
127
Study length
about 4.2 years
Ages
45–75
Locations
27 sites in CA, CO, DC +14
About this study
This trial is testing a treatment called AAV2-GDNF gene therapy for adults with moderate Parkinson's Disease. The treatment involves delivering the gene to the putamen, and it will be compared to control surgery.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take AAV2-GDNF gene therapy
- 2.Undergo control surgery
PhasePhase 2
Primary goalChange from baseline to Month 18 on PD Motor Diary
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Change from baseline to Month 18 on PD Motor Diary
Body systems
Neurology